Fiche centre
London Health Sciences Centre
London — Canada
Essais liés22clinical trials
VilleLondonlocalisation
PaysCanadalocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07680322
Essais cliniques associés
22| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| LY4256984 | Sclérose latérale amyotrophique | Phase 1 | NCT07100119 | A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis | RECRUITING |
| Nabilone | Alzheimer | Phase 3 | NCT04516057 | NAB-IT — Nabilone for Agitation Blinded Intervention Trial | RECRUITING |
| Physiology-guided NCL PCI | Maladie coronarienne | Non applicable | NCT05701358 | COMPLETE-2 — Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease | ACTIVE_NOT_RECRUITING |
| Colchicine 0.5 MG Oral Tablet | Maladie coronarienne | Phase 3 | NCT04774159 | LEADER-PAD — Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk | RECRUITING |
| Ataluren | Myopathies | Phase 3 | NCT01247207 | Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD) | TERMINATED |
| AV078 | Épilepsie | Phase 2 | NCT07680322 | Safety and Efficacy of AV078 in Participants With Tuberous Sclerosis Complex (TSC) Refractory Epilepsy (RESTOR-1) | NOT_YET_RECRUITING |
| NS-089/NCNP-02 | Myopathies | Phase 2 | NCT05996003 | NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD) | ACTIVE_NOT_RECRUITING |
| Tacabrutideg | Cancer | Phase 3 | NCT06846671 | CaDAnCe-302 — A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors | RECRUITING |
| Zanidatamab | Cancer | Phase 3 | NCT06282575 | Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer | RECRUITING |
| NS-050/NCNP-03 | Myopathies | Phase 1/2 | NCT06053814 | NS-050/NCNP-03 in Boys With DMD (Meteor50) | ACTIVE_NOT_RECRUITING |
| Erenumab Dose 1 | Migraine | Phase 3 | NCT03832998 | OASIS(CM) — Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine | COMPLETED |
| CBD | Alzheimer | Phase 2 | NCT06014424 | CALM-IT — Cannabidiol Medication Intervention Trial | RECRUITING |
| Apalutamide 60mg Tab | Cancer | Phase 2 | NCT04812366 | GUNS — Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer | RECRUITING |
| Mycophenolate Mofetil | Myasthénie | À vérifier | NCT03490539 | PROMISE-MG — Disease-Modifying Treatments for Myasthenia Gravis | COMPLETED |
| Pozelimab + Cemdisiran | Myasthénie | Phase 3 | NCT05070858 | NIMBLE — A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| DYNE-251 | Myopathies | Phase 1/2 | NCT05524883 | DELIVER — Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping | ACTIVE_NOT_RECRUITING |
| Erenumab Dose 1 | Migraine | Phase 3 | NCT03836040 | OASIS(EM) — Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine | ACTIVE_NOT_RECRUITING |
| Fosigotifator | Sclérose latérale amyotrophique | Phase 1 | NCT04948645 | A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis | TERMINATED |
| Clinical Trial of Vitamin E to Treat Muscular Cramps in Patients With ALS | Sclérose latérale amyotrophique | Phase 3 | NCT00372879 | Clinical Trial of Vitamin E to Treat Muscular Cramps in Patients With ALS | COMPLETED |
| Efgartigimod PH20 SC | Myasthénie | Phase 3 | NCT06558279 | ADAPT oculus — A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| Sacituzumab govitecan-hziy | Cancer | Phase 3 | NCT06486441 | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) | ACTIVE_NOT_RECRUITING |
| The Ontario Neurodegenerative Disease Research Initiative | Sclérose latérale amyotrophique | À vérifier | NCT04104373 | The Ontario Neurodegenerative Disease Research Initiative | COMPLETED |